CSL Ltd
ASX:CSL
CSL Ltd
ASX:CSL
Price:
181.24
AUD
-0.25%
Market Cap:
AU$87.9B
Relative Value
The Relative Value of one
CSL
stock under the Base Case scenario is
223.54
AUD.
Compared to the current market price of 181.24 AUD,
CSL Ltd
is
Undervalued by 19%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CSL
Relative Value
Base Case
223.54
AUD
Undervaluation 19%
Multiples Across Competitors
CSL Competitors Multiples
CSL Ltd Competitors
CSL Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
CSL Ltd
ASX:CSL
|
87.9B AUD | 3.9 | 20.3 | 13.6 | 17 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
386.2B USD | 6.5 | 164.5 | 16 | 22.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
196.7B USD | 5.5 | 28.1 | 19.9 | 19.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
185.2B USD | 6.4 | 22.8 | 15.5 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.4B USD | 9.9 | 31.7 | 23.2 | 24.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.9B USD | 5.6 | 18 | 15.2 | 17.4 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.9B EUR | 14.5 | 34 | 58.1 | 59.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
43.8B USD | 13.6 | 1 000.8 | 134.8 | 163.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
